XII International Pharma Licensing Symposium (XII IPLS)

Event Details

  • Location: Berlin, Germany
  • Dates: Wednesday 16th September to Friday 18th September 2015
  • Price:
    (Non-Members: €1025.00)

Just IPLS Text Logo

‘The Disappearing Deal World?’

How Companies Secure Deals in an Environment of

Big Pharma M&A and Strategic Alliances


We are pleased to announce the XII International Pharma Licensing Symposium, hosted by the Pharma Lizenz Club Deutschland (PLCD), will be held on 16th – 18th September 2015 at the Hilton Berlin, Germany.

Details of the 3 day programme will be announced very shortly but the highlights of the event will include:

– Access to Online Delegate Contact Systen

– Private Area for One-to-One Meetings

– Presentations from Speakers within the Indsutry

– ‘Interactive ‘Talking Tables’ and Panel Discussions

– Informal Networking Opportunites

– Welcome Drinks Reception plus Gala Dinner at The Adagio


‘Since I started to attend your conference three years ago, about USD150m investment in 5 deals has been done. Of these 5 deals, at least two of them (more than USD 100m) are coming from the leads, generated from the one2one meetings in your conference. I feel that I own a great debt to your conference’

Previous IPLS delegate

Programme (please see full programme below) – to include:

– Overview of what is happening in the deal environment

– Panel sessions featuring different healthcare sectors explaing how M&A affects their business

– Consolidation and risk sharing between big pharma companies

– 6 ‘Talking Table’ topics – Good Partnering Practices in the Healthcare Industry

For further information please contact Adam Collins, PLG Administrator:

00 44 (0)1737 356391

Contact a Delegate

Send a message to another attendee of this event

Please enter your email address* and the password provided by PLG to send a message.

* Please enter the email address used to register for this event.

Event Sponsors

Event Schedule

Wednesday 16th September

09.00 - 10.00 Registration
10.00 - 10.15 Welcome and Introduction
IRINA STAATZ-GRANZER, President, Pharma Lizenz Club Deutschland (PLCD)
Deal Environment Review Across The Healthcare Sector Explaining How M&A is Affecting Their Business
10.15 - 10.45 Innovation: Where Are New Products Coming From? Are the Pharma Company Pipelines Empty?
JONATHAN DE PASS, Chairman, Evaluate
10.45 - 11.15 Recent Trends in Medical Devices Business Development
AMIR BABAEI-MAHANI, Senior Director External Innovation & Enabling Technologies, DePuy Synthes, Companies of Johnson & Johnson
11.15 - 11.45 M&A From the OTC Perspective
THORSTEN UMLAND, VP and Head, Business Development & Licensing Consumer Care, Bayer HealthCare
11.45 - 12.15 Generics Viewpoint: The Impact of M&A Activity on Deals
CLAUDIO ALBRECHT, Co-Founder and Managing Partner, Albrecht, Prock & Partners
12.15 - 13.00 Panel Discussion
13.00 - 14.30 Lunch
14.30 - 17.00 SESSION B
Good Partnering Practices in the Healthcare Industry - a Swiss HLG Initiative:
1. Scouting & Prospecting
2. Evaluation and Due Diligence
3. Negotiation & Execution
4. Intergration & Alliance Management
5. Conflict Resolution and Termination
6. Breaking Through the Invisible Cultural Boundaries Within Europe

Each Table Will Be Run Twice
17.00 - 19.00 Networking Drinks Reception
Hilton Berlin Ballroom Foyer Area

Thursday 17th September

09.00 - 09.30 Feedback and Conclusions from Previous Days Talking Tables
Consolidation and Risk Sharing Between Big Pharma Companies
09.30 - 10.15 Practical BD Experience of Risk Sharing, Co-Development and Co-Commercialisation
JOESPH HAVRILLA, Head of Alliance Management, Bayer HealthCare
10.15 - 11.00 Partnership Deals - Strengths and Risk Sharing
JUERGEN BECK, Head of Business Development & Licensing / Strategic Transactions, Boehringer Ingelheim
11.00 - 11.30 Break
Impact of the Changing Deal Environment for Mid-Sized Companies
11.30 - 12.15 Market Access
BIRGIT FRIEDMANN, Senior Director, Market Access, Quintiles
12.15 - 13.00 2016 Transactional Trends: Key Issues for Cross Border Deals; Focus on Emerging and Mid-Sized Companies
GREG BENNING, Managing Director, Head of Financial Advisory & MARK A. KING, Senior Partner, Back Bay Life Science Advisors
13.00 - 14.00 Lunch
Challenges Securing Deals in Other Countries
14.00 - 14.45 Opportunities & Difficulties in Emerging Markets for Non-Generic Products
REINER CHRISTENSEN, CEO, Chameleon Pharma Consulting
14.45 - 15.30 Japan: Cultural Differences Impact on Deal Making
15.30 - 16.00 Break
16.00 - 16.45 Bringing Pharmaceutical Products to China: Opportunities and Challenges
HUAIZHENG PENG, General Manager, International Operations, China Medical System Holdings
16.45 - 17.30 Business Development in India: More Than Just Generics
RAVI SODHA, Senior Director, Business Development, Actelion Pharma
18.00 - 22.00 Drinks Reception and Gala Dinner at Adagio
Dress Code: Business Suits

Friday 18th September

Business Models Proving Resistant to Pharma M&A
09.00 - 09.45 Deal Structure Evolution: Morphing Into a Biopharma Company by Doing Major Pharma Deals
BARBARA KREBS-POHL, Head of Business Development, MorphoSys
09.45 - 10.30 How Bavarian Nordic Built a Multi-Million Business and Commercial Infrastructure Through Deal-Making
JUERGEN LANGHAERIG, VP Business Development, Bavarian Nordic
10.30 - 11.00 Break
11.00 - 11.45 Orphan Drugs Strategy
DANKWART RAUSCHER, Head of Portfolio & Licensing Management, Recordati Pharma
11.45 - 12.30 Deal Making in the New Financial Environment: Results of the PLG Healthcare Deals Finance Survey
KLAUS MALECK, CEO, Tetec & ROGER DAVIES, Director, Redpharma
12.30 - 14.00 Lunch and CLOSE

Venue & Accommodation

Full Venue Address

Hilton Berlin
Mohrenstrasse 30,
10117 Berlin,

Visit Venue Website

View Map

Event Downloads

You must be logged in to access the downloads.